Roivant Sciences
In David Einhorn's portfolio · Greenlight Capital
Ticker ROIV
Still in the portfolio as of Q3 2026. Every quarter it shows up in a Greenlight Capital 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2026 | Reduce 47% | 1,131,747 | 1.2% |
| Q2 2026 | No change | 2,152,669 | 1.9% |
| Q1 2026 | Add 4% | 2,152,669 | 1.9% |
| Q4 2025 | Reduce 9% | 2,069,309 | 1.6% |
| Q3 2025 | Reduce 50% | 2,275,529 | 1.4% |
| Q2 2025 | Reduce 16% | 4,551,057 | 2.2% |
| Q1 2025 | Add 3% | 5,441,167 | 2.8% |
| Q4 2024 | Reduce 1% | 5,271,067 | 3.2% |
| Q3 2024 | Add 10% | 5,308,040 | 2.5% |
| Q2 2024 | Add 15% | 4,810,960 | 2.5% |
| Q1 2024 | Buy | 4,190,490 | 2.0% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.